PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 & -2)”

The above is a plain language summary of an article/abstract published in a peer-reviewed scientific journal. The content is not peer-reviewed. Unless otherwise specified, the content on this website has undergone a medical, legal, and regulatory (MLR) review and approval process by Boehringer Ingelheim. The publisher of the original manuscript was not involved in the preparation of this PLS and has neither reviewed nor approved its content.